Visionary Asset Management Inc. Takes Position in Sanofi (NYSE:SNY)
Visionary Asset Management Inc. purchased a new stake in shares of Sanofi (NYSE:SNY) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 6,720 shares of the company’s stock, valued at approximately $322,000.
Several other institutional investors have also made changes to their positions in the stock. Harbour Capital Advisors LLC acquired a new position in shares of Sanofi during the first quarter valued at $113,000. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in shares of Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock valued at $171,000 after buying an additional 3,713 shares in the last quarter. BLB&B Advisors LLC acquired a new position in shares of Sanofi during the first quarter valued at $202,000. Huntington National Bank raised its position in shares of Sanofi by 3.4% in the first quarter. Huntington National Bank now owns 4,455 shares of the company’s stock valued at $202,000 after buying an additional 147 shares in the last quarter. Finally, New England Research & Management Inc. acquired a new position in shares of Sanofi during the first quarter valued at $208,000. Hedge funds and other institutional investors own 9.84% of the company’s stock.
Sanofi (SNY) traded up 2.50% during midday trading on Thursday, reaching $47.98. The company had a trading volume of 2,443,425 shares. The firm’s 50 day moving average is $48.41 and its 200 day moving average is $45.37. The stock has a market capitalization of $121.17 billion, a PE ratio of 11.63 and a beta of 0.89. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24.
Sanofi (NYSE:SNY) last issued its earnings results on Friday, April 28th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.03. Sanofi had a net margin of 26.55% and a return on equity of 25.89%. The company had revenue of $8.65 billion during the quarter, compared to analysts’ expectations of $8.40 billion. Sanofi’s revenue for the quarter was up 1.2% on a year-over-year basis. On average, equities analysts anticipate that Sanofi will post $3.20 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Visionary Asset Management Inc. Takes Position in Sanofi (NYSE:SNY)” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.dailypolitical.com/2017/07/20/visionary-asset-management-inc-takes-position-in-sanofi-nysesny.html.
SNY has been the subject of several recent analyst reports. TheStreet upgraded Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. Argus initiated coverage on Sanofi in a research note on Thursday, April 6th. They issued a “buy” rating and a $50.00 price target for the company. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $50.00 price target for the company in a research note on Tuesday, April 11th. BidaskClub upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Finally, Berenberg Bank lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. Sanofi presently has an average rating of “Hold” and an average price target of $67.67.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.